Cooperative Agreement U43CA221567

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) will support Phase I clinical testing of a novel therapeutic agent, termed MN-Anti-miR10B or TTX-MC138, developed by Transcode Therapeutics, Inc. The therapy aims to selectively target and eradicate metastatic tumor cells by inhibiting miRNA-10B, a validated driver of metastasis. Preclinical studies have shown the therapy can mediate regression of metastases in animal models with no evidence of...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $546,625.00 to the University of Pittsburgh to develop a novel nanocarrier-based immunochemotherapy for the treatment of metastatic colorectal cancer (mCRC). The key products and services to be delivered include: Developing and characterizing a nanoparticle carrier capable of co-delivering small interfering RNA targeting the IRHOM1 protein and a prodrug conjugate of...

This $122,577 Project Grant awarded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) supports research to develop and characterize self-amplifying RNA lipid nanoparticles for gene delivery to solid tumors. The primary aims are to: 1) Screen and optimize the self-amplifying RNA and lipid nanoparticle formulation for efficient gene delivery across multiple tumor types, using a gene drive cassette to selectively express a suicide gene in tumors; and 2) Maximize the...

The National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), awarded a $400,000 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Nuago Therapeutics Inc. on September 19, 2024. The goal of this STTR project is to develop an RNA interference-based therapeutic to treat prostate cancer. The therapeutic, termed "NU002", will use lipopolyplex nanoparticles to deliver short interfering RNAs (siRNAs) derived from CAG trinucleotide repeat sequences....

The University of California, Davis was awarded a $615,399 Project Grant by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to develop a transformable nanoparticle (TNP) platform capable of transforming into nanofibrillar networks that can effectively deliver immunomodulatory peptides, small molecules, and proteins to the tumor microenvironment. This 5-year research project aims to optimize the TNP/TCTS therapeutic platform for on-demand modulation of the tumor...

This $503,194 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at Seattle Children's Hospital aimed at developing an innovative multispecific T cell engager (MTE) therapy to treat neuroblastoma and other pediatric solid tumors. The key products and services being delivered under this 2-year award include: 1) Determining the efficacy of the R2P3 MTE, which binds to the ROR1 and PD-L1 tumor targets as well as CD3 on T cells,...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $644,034 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop a nanoparticle-based drug delivery platform that uses radiation therapy to trigger the localized release of chemotherapy within tumor tissue. The goal is to improve the therapeutic window of chemoradiation treatment by enhancing tumor control while mitigating systemic toxicities....

The National Cancer Institute (NCI) awarded a $185,760 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Regents of the University of California, San Francisco (UCSF) to develop a novel tumor-targeted combination therapy for metastatic castration-resistant prostate cancer (mCRPC). The project aims to enhance efficacy and reduce toxicity by co-delivering cytotoxic drugs and the radioactive isotope Actinium-225 directly to cancer cells. Key objectives include developing...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $400,000 to Senex Biotechnology Inc. to develop a nanoparticle formulation of a mediator kinase inhibitor drug candidate, SNX631-6, for the treatment of peritoneal ovarian cancer metastases. The goal is to optimize the nanoparticle formulation for improved pharmacokinetics and efficacy compared to oral administration when delivered intraperitoneally. The project will assess the...